Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neumirna Therapeutics

Request full access

RNA drugs targeting microRNAs in neurological disease

Copenhagen, DenmarkFounded 2020Biotech & Life Sciences

About Neumirna Therapeutics

Neumirna Therapeutics is a Copenhagen-based biotech company developing antisense oligonucleotide (ASO) drugs that target microRNAs, small RNA molecules that regulate gene expression and help drive chronic neurological disease. By blocking disease-linked microRNAs, it aims to slow or reverse disease progression rather than only manage symptoms.

Its lead candidate, NMT.001, is an anti-miR ASO that inhibits miR-134 for drug-resistant epilepsy, a target first linked to seizures by researchers at RCSI and FutureNeuro in Dublin; clinical trials are planned for 2027. NMT.002 targets miR-27b in Parkinson's disease, and two further undisclosed programmes are in early screening. An in-house platform takes programmes from target identification through ASO design, screening and in vivo proof of concept.

The company works with academic partners including Aalborg University's Center for RNA Medicine and RCSI, and runs a team across Copenhagen, Basel and Boston. Its business model is to advance its own drug candidates through clinical development for patients with poorly served neurological disorders.

Source: Dealroom company data

At a glance

Status
Operational
Employees
19
Open positions
None listed
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Drug Development, Neurology, Epilepsy, RNA, mRNA Medicines, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2025 $22M $88M Angelini Ventures · Innovestor · Invivo Partners ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearProfitMargin
2026 —
2025 —
2024 —
2023 —
2022 —
2021 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Neumirna Therapeutics website traffic

Latest recorded traffic for Neumirna Therapeutics is 540 monthly website visits, down 41.3% over the last three months. Neumirna Therapeutics's team grew 58.3% over the past year.

Latest monthly visits540 3-month web change-41.3% 1-year team growth+58.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Neumirna Therapeutics in the Copenhagen ecosystem

Live from Dealroom

The Neumirna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Angelini Ventures
  • Innovestor
  • Invivo Partners
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇩🇰 Denmark64.7%
🇨🇭 Switzerland11.8%
🇫🇮 Finland11.8%
🇸🇬 Singapore5.9%
🇪🇸 Spain5.9%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neumirna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neumirna Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.